Details for New Drug Application (NDA): 213994
✉ Email this page to a colleague
The generic ingredient in EPHEDRINE SULFATE is ephedrine sulfate. There are sixty-eight drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ephedrine sulfate profile page.
Summary for 213994
Tradename: | EPHEDRINE SULFATE |
Applicant: | Endo Operations |
Ingredient: | ephedrine sulfate |
Patents: | 2 |
Pharmacology for NDA: 213994
Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
Physiological Effect | Increased Norepinephrine Activity |
Medical Subject Heading (MeSH) Categories for 213994
Suppliers and Packaging for NDA: 213994
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213994 | NDA | ENDO USA, Inc. | 42023-243 | 42023-243-01 | 10 mL in 1 VIAL, SINGLE-DOSE (42023-243-01) |
EPHEDRINE SULFATE | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213994 | NDA | ENDO USA, Inc. | 42023-243 | 42023-243-99 | 10 mL in 1 VIAL, SINGLE-DOSE (42023-243-99) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 50MG/10ML (5MG/ML) | ||||
Approval Date: | Oct 16, 2020 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 22, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 25MG/5ML (5MG/ML) | ||||
Approval Date: | Apr 22, 2022 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 22, 2040 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 22, 2040 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF CLINICALLY IMPORTANT HYPOTENSION OCCURRING IN THE SETTING OF ANESTHESIA |
Complete Access Available with Subscription